Asia Pacific Pharmacokinetics Services Market
The Asia Pacific Pharmacokinetics Services Market size was valued at US$ 191.44 Mn in 2023 and is projected to reach US$ 356.58 Mn by 2031, growing at a CAGR of 8.1% during 2023 - 2031.
Report Coverage
- Drug Type: Small Molecule, Large Molecule, Vaccines
- Service Type: Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis
- End User: Pharmaceutical and Biotechnology Companies, Contract Research Organization
US$ 191.44 Mn
Market size in 2023
US$ 356.58 Mn
Market Size by 2031
8.1%
CAGR, 2023 - 2031
2024-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Pharmacokinetics Services Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Pharmacokinetics Services Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Pharmacokinetics Services Market Regional Analysis
6.2 Asia Pacific Pharmacokinetics Services Market Revenue 2021-2031 (US$ Million)
6.3 Asia Pacific Pharmacokinetics Services Market Forecast Analysis
7. Asia Pacific Pharmacokinetics Services Market Analysis – by Drug Type
7.1 Small Molecule
- 7.1.1 Overview
- 7.1.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Large Molecule
- 7.2.1 Overview
- 7.2.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Vaccines
- 7.3.1 Overview
- 7.3.2 Vaccines: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Asia Pacific Pharmacokinetics Services Market Analysis – by Service Type
8.1 Pre-Clinical ADME and Human Studies
- 8.1.1 Overview
- 8.1.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 PK/PD Analysis and Reporting
- 8.2.1 Overview
- 8.2.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Dosing Simulations
- 8.3.1 Overview
- 8.3.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Risk Analysis
- 8.4.1 Overview
- 8.4.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Asia Pacific Pharmacokinetics Services Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Contract Research Organization
- 9.2.1 Overview
- 9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Asia Pacific Pharmacokinetics Services Market – Asia-Pacific Analysis
10.1 Overview
10.2 Asia-Pacific- 10.2.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Country, 2024 and 2031 (%)
- 10.2.1.1 Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 China: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
- 10.2.1.1.2 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
- 10.2.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
- 10.2.1.2 India: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
- 10.2.1.2.2 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
- 10.2.1.2.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
- 10.2.1.3 Japan: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
- 10.2.1.3.2 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
- 10.2.1.3.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
- 10.2.1.4 Australia: Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
- 10.2.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
- 10.2.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
- 10.2.1.5 Rest of Asia-Pacific : Asia Pacific Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type
- 10.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type
- 10.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Pharmacokinetics Services Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Allucent
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Certara Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Eurofins Scientific SE
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 PACIFIC BIOLABS
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Parexel International Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 SGS SA
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Shanghai Medicilon Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Thermo Fisher Scientific Inc.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full A Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
